Saphris (Asenapine Maleate) Patent Expiration, LOE Window & CMS Spending
Saphris (Asenapine Maleate) by AbbVie: FDA Orange Book core substance LOE 2026-10-06, 3 AB generics, $26.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N022117 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2026-10-06 |
| Last Listed Patent or Exclusivity Date | 2026-10-06 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $26.7M |
| 2024 Medicare Part D Spend | $7.2M |
| 2024 Medicaid Spend | $19.5M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.